CLOs on the Move

OXiGENE

www.oxigene.com

 
OXiGENE is a biopharmaceutical company developing new and improved therapeutics that have the potential to deliver significant medical benefits to patients with cancer and serious medical conditions. Our primary focus is developing first-in-class anti-vascular drugs referred to as vascular disrupting agents (VDAs). Our lead compound in clinical development is fosbretabulin. VDAs are a new and highly differentiated class of anti-vascular drug that target existing tumor vasculature, leading to extensive tumor cell death. VDAs target the tumor vasculature rather than the tumor cells and therefore have broad potential therapeutic utility in cancer. Because VDAs act differently than anti-angiogenic drugs or cytotoxic chemotherapy drugs, ...
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.oxigene.com
  • 701 Gateway Blvd Suite 210
    South San Francisco, CA USA 94080
  • Phone: 650.635.7000

Executives

Name Title Contact Details

Similar Companies

Surgical Technologies

Surgical Technologies is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sysmex

Sysmex America, Inc. distributes and supports automated `in vitro` diagnostic hematology, coagulation and urinalysis analyzers, reagents, and information systems for laboratories and healthcare facilities throughout the Western Hemisphere.? The company was formerly known as Sysmex Corporation Of America and changed its name to Sysmex America, Inc. in June 2003. The company was founded in 1979 and is based in Lincolnshire, Illinois. Sysmex America, Inc. operates as a subsidiary of Sysmex Corp.

Intersect ENT

Intersect ENT (Nasdaq:XENT) is a medical technology company dedicated to advancing the treatment of ear, nose and throat (ENT) conditions through evidence-based innovation, providing physicians with solutions to overcome clinical challenges and improve the quality of life for patients.

B and L Biotech

B & L Biotech is a Bala Cynwyd, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AngioDynamics

Founded in 1988 in Queensbury, N.Y., U.S., AngioDynamics is today a NASDAQ-listed public company. We are a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease. Our diverse product line includes market-leading radiofrequency ablation and NanoKnife® systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. AngioDynamics has distinguished itself as a dynamic brand in a technologically competitive, high-growth industry, through the company`s consistent ability to successfully develop and bring to market new technologies and products. AngioDynamics believes it is well poised to continue that trend. Looking into the future, the company plans to bring forth a continuing stream of innovations that greatly improve patient care by providing the highest-quality, best-performing products.